{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:49:51Z","timestamp":1786736991838,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Family Med Prim Care"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/jfmpc.jfmpc_171_20","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T04:42:48Z","timestamp":1593405768000},"page":"2758","source":"Crossref","is-referenced-by-count":4,"title":["Economic impacts of the Bacillus Calmette-Gu\u00e9rin (BCG) therapy shortage and the proposed solutions for patients with non-muscle invasive bladder Cancer in Aseer Province, Saudi Arabia"],"prefix":"10.4103","volume":"9","author":[{"given":"MishariHM","family":"Alshyarba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Alamri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AlhassanAlamer","family":"Assiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2249-4863.287837-1","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer; 2010. Available from: http:\/\/globocan.iarc.fr\/. [Last accessed on 2016 Mar 16]."},{"key":"key-10.4103\/2249-4863.287837-2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"key-10.4103\/2249-4863.287837-3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1464-410X.2007.07239.x","article-title":"Declining mortality from bladder cancer in Europe","author":"Ferlay","year":"2008","journal-title":"BJU Int"},{"key":"key-10.4103\/2249-4863.287837-4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"key-10.4103\/2249-4863.287837-5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non- muscle-invasive bladder cancer","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"key-10.4103\/2249-4863.287837-6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"key-10.4103\/2249-4863.287837-7","first-page":"1964","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"key-10.4103\/2249-4863.287837-8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JOP.2011.000480","article-title":"Adjuvant intravesical bacillus Calmette-Gu\u00e9rin therapy and survival among elderly patients with non-muscle-invasive bladder cancer","author":"Spencer","year":"2013","journal-title":"J Oncol Pract"},{"key":"key-10.4103\/2249-4863.287837-9","unstructured":"Mould at Toronto plant may affect supplies of cancer drug. Canadian Press Web site. Available from: http:\/\/www.cbc.ca\/news\/canada\/toronto\/mould-at-toronto-plant-may-affect-supplies-of-cancer-drug-1.1282152. [Last accessed on 2014 Nov 04]."},{"key":"key-10.4103\/2249-4863.287837-10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: Costs and considerations of caring for this disease","author":"Svatek","year":"2014","journal-title":"Eur Urol"},{"key":"key-10.4103\/2249-4863.287837-11","doi-asserted-by":"crossref","unstructured":"Rieken M, Shariat SF, Kluth L, Crivelli JJ, Abufaraj M, Foerster B, et al. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. Urol Oncol Semin Orig Investig 2018;36:8.e17-24.","DOI":"10.1016\/j.urolonc.2017.08.027"},{"key":"key-10.4103\/2249-4863.287837-12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"key-10.4103\/2249-4863.287837-13","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMp1615697","article-title":"Ensuring access to injectable generic drugs: The case of intravesical BCG for bladder cancer","author":"Davies","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2249-4863.287837-14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-179018","article-title":"The BCG shortage","author":"Messing","year":"2017","journal-title":"Bladder Cancer"},{"key":"key-10.4103\/2249-4863.287837-15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU Cancers Group randomized study of maintenance Bacillus Calmette-Gu\u00e9rin in inter- mediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: One- third dose versus full dose and 1 year versus 3 years of maintenance","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"key-10.4103\/2249-4863.287837-16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: A systematic review of the published results of randomized clinical trials","author":"Sylvester","year":"2008","journal-title":"Eur Urol"},{"key":"key-10.4103\/2249-4863.287837-17","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high- risk non-muscle-invasive bladder cancer","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"key-10.4103\/2249-4863.287837-18","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","article-title":"Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma","author":"Colombo","year":"2003","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/2249-4863.287837-19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","article-title":"The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of nonmuscle-invasive bladder cancer: A systematic review","author":"Lammers","year":"2011","journal-title":"Eur Urol"},{"key":"key-10.4103\/2249-4863.287837-20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fonc.2017.00260","article-title":"Intravesical gemcitabine versus intravesical Bacillus Calmette-Guerin for the treatment of non-muscle invasive bladder cancer: An evaluation of efficacy and toxicity","author":"Prasanna","year":"2017","journal-title":"Front Oncol"},{"key":"key-10.4103\/2249-4863.287837-21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1464-410X.2011.10880.x","article-title":"Intravesical gemcitabine therapy for nonmuscle invasive bladder cancer (NMIBC): A systematic review","author":"Shelley","year":"2012","journal-title":"BJU Int"},{"key":"key-10.4103\/2249-4863.287837-22","first-page":"1893","article-title":"Gemcitabine versus Bacille Calmette-Gu\u00e9rin after initial Bacille Calmette-Gu\u00e9rin failure in nonmuscle- invasive bladder cancer","author":"Di","year":"2010","journal-title":"Cancer"},{"key":"key-10.4103\/2249-4863.287837-23","first-page":"CD009294","article-title":"Intravesical gemcitabine for nonmuscle invasive bladder cancer","author":"Jones","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/2249-4863.287837-24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/2249-4863.287837-25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000273461","article-title":"Bacillus Calmette-Gu\u00e9rin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: A randomised prospective study","author":"Porena","year":"2010","journal-title":"Urol Int"},{"key":"key-10.4103\/2249-4863.287837-26","doi-asserted-by":"crossref","unstructured":"D'Andrea D, Abufaraj M, Susani M, Ristl R, Foerster B, Kimura S, et al. Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. Urol Oncol 2018;36:239.e1-7.","DOI":"10.1016\/j.urolonc.2018.01.018"},{"key":"key-10.4103\/2249-4863.287837-27","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1056\/NEJMp1800861","article-title":"Addressing generic-drug market failures: The case for establishing a nonprofit manufacturer","author":"Liljenquist","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:48:40Z","timestamp":1786733320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_171_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"alternative-id":["287837"],"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_171_20","relation":{},"ISSN":["2249-4863"],"issn-type":[{"value":"2249-4863","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}